Video Shorts

0:44

Reducing Time to Breast Cancer Screening and Diagnosis

4 months ago

Martha Welman, MD

0:41

Exploring the Significance of a Pembrolizumab-Based Regimen in Ovarian Cancer

4 months ago

Emese Zsiros, MD, PhD

1:11

Targeting ENPP3 in RCC

4 months ago

Randy F. Sweis, MD

1:00

Prostate Cancer Topics to Watch at ASCO GU 2026

4 months ago

Mehmet Asim Bilen, MD

0:49

Bladder Cancer Abstracts to Watch at ASCO GU 2026

4 months ago

Jad Chahoud, MD, MPH, MHA

1:47

Zanzalintinib Plus Atezolizumab Is One Step Closer to FDA Approval in Previously Treated mCRC

4 months ago

Anwaar Saeed, MD

1:22

Kidney Cancer Abstracts to Watch at ASCO GU 2026

4 months ago

Jad Chahoud, MD, MPH, MHA

Malin Hultcrantz, MD, PhD, discusses FDA draft guidance on MRD end points in multiple myeloma clinical trials.

1:03

FDA Draft Guidance on MRD End Points in Myeloma Trials

4 months ago

Malin Hultcrantz, MD, PhD

0:41

Overused Buzzwords in Hematology and Oncology

4 months ago

Riley Kandel

0:31

Tackling Lifileucel in Metastatic Melanoma and Other Topics at TCT 2026

4 months ago

Amrita Desai, MD, MPH

0:37

Hematologic Oncologists Share Conference Must-Haves

4 months ago

Riley Kandel

0:34

Zanidatamab-Based Regimens Could Be A ‘Game Changer’ for First-Line HER2+ GEA Paradigm

4 months ago

Raji Shameem, MD

1:40

TCT 2026: CAR T-Cell Therapy Expert Insights

4 months ago

Ashling Wahner

Philippos Costa, MD, and Hari Deshpande, MD

0:2.02

International Chondrosarcoma Awareness Day: Targeted Therapies Gain Ground in Rare Bone Cancer

4 months ago

Philippos Costa, MD(+1 more)

0:28

Previewing Loncastuximab Tesirine in Heavily Pretreated Patients With Diffuse Large B-Cell Lymphoma

4 months ago

Fernando Gibran-Nunes, MD

0:58

Prophylactic Dexamethasone Mitigating Neurotoxicity in Multiple Myeloma

4 months ago

Kenneth Jin Chang Lim, MBBS

1:24

The Role of Molecular and Genetic Testing in Ph+ Acute Lymphoblastic Leukemia

4 months ago

Nicholas J. Short, MD

1:05

5-Year Data Update from the Phase 2 ELARA Trial

4 months ago

Peter Riedell, MD

0:55

Tackling the Barriers to Cervical Cancer Screening

4 months ago

Robert Neff, MD

4:00

OncLive Recognizes World Cancer Day

4 months ago

Ronac Mamtani, MD, MSCE(+3 more)

0:43

Unpacking OS Data from the ROSELLA Trial

4 months ago

Alexander B. Olawaiye, MD

Justin Call, MD, and D. Ross Camidge, MD, PhD

2:11

How I Discovered My True Calling in Oncology

4 months ago

Ross Camidge, MD, PhD(+1 more)

1:43

Optimizing HPV Vaccination for Cancer Prevention

4 months ago

Maurie Markman, MD

1:49

Implications of FDA Draft Guidance on MRD End Points in Myeloma Trials

4 months ago

Rahul Banerjee, MD

0:21

Outlining the Results of the HER2CLIMB-05 Trial in HER2+ Breast Cancer

4 months ago

Erika P. Hamilton, MD

0:54

Increasing Clinical Trial Access in Gynecologic Oncology

4 months ago

Katherine Kurnit, MD, MPH

1:25

Highlighting the Importance of the Bionic Breast Program

4 months ago

Stacy Tessler Lindau, MD, MA

0:38

The Role of Clinical Trials in Gynecologic Oncology

4 months ago

John Moroney, MD

1:22

Expert Insight on AI in Oncology and Clinical Trials at University of Chicago Comprehensive Cancer Center

4 months ago

Riley Kandel

1:18

Examining the Future of Bispecifics and CAR T-Cell Therapy in Lymphoma

4 months ago

Alexandra Rojek, MD

Video Shorts

Trending on OncLive

Vopimetostat Plus Daraxonrasib Yields 92% ORR in MTAP-Deleted, RAS-Mutant Pancreatic Cancer

KEYNOTE-D46 Trial Is Discontinued With Sacituzumab Govitecan Plus Pembrolizumab in PD-L1–High NSCLC

GU Cancer Experts Highlight the Most Impactful and Discussion-Worthy Data Presented at ASCO 2026

Subcutaneous Isatuximab Administered Via OBI Approved in EU for Multiple Myeloma

May’s GI Monthly Rewind: A Landmark Approval in CCA, Expanded Access for Daraxonrasib, and More Key Pipeline Updates